Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PODD 
Insulet Corporation (PODD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: PODD (1-star) is a SELL. SELL since 2 days. Simulated Profits (-7.77%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
23 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $378.21
1 Year Target Price $378.21
| 14 | Strong Buy |
| 6 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 12.51% | Avg. Invested days 47 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.24B USD | Price to earnings Ratio 91.84 | 1Y Target Price 378.21 |
Price to earnings Ratio 91.84 | 1Y Target Price 378.21 | ||
Volume (30-day avg) 23 | Beta 1.38 | 52 Weeks Range 230.05 - 354.88 | Updated Date 12/4/2025 |
52 Weeks Range 230.05 - 354.88 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-06 | When Before Market | Estimate 1.14 | Actual 1.24 |
Profitability
Profit Margin 9.76% | Operating Margin (TTM) 16.66% |
Management Effectiveness
Return on Assets (TTM) 8.74% | Return on Equity (TTM) 19.68% |
Valuation
Trailing PE 91.84 | Forward PE 49.51 | Enterprise Value 21891785010 | Price to Sales(TTM) 8.82 |
Enterprise Value 21891785010 | Price to Sales(TTM) 8.82 | ||
Enterprise Value to Revenue 8.68 | Enterprise Value to EBITDA 48.51 | Shares Outstanding 70346898 | Shares Floating 70071138 |
Shares Outstanding 70346898 | Shares Floating 70071138 | ||
Percent Insiders 0.28 | Percent Institutions 100.98 |
Upturn AI SWOT
Insulet Corporation
Company Overview
History and Background
Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts. It pioneered the Omnipod Insulin Management System, offering a tubeless alternative to traditional insulin pumps. Initially focused on simplicity and ease of use, the company has grown to become a major player in the diabetes technology market.
Core Business Areas
- Insulin Delivery Systems: Insulet's primary focus is the design, development, manufacture, and commercialization of the Omnipod Insulin Management System and its related components. This includes the Omnipod DASH and Omnipod 5 automated insulin delivery system, as well as associated products and services.
Leadership and Structure
As of the latest update, Jim Hollingsworth serves as the President and Chief Executive Officer. The company operates with a functional organizational structure, emphasizing innovation and commercial excellence in the diabetes care sector. The board of directors provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Omnipod 5: The Omnipod 5 is an automated insulin delivery (AID) system featuring a tubeless pod that delivers insulin based on continuous glucose monitoring (CGM) readings. The system adapts insulin delivery to help protect against highs and lows. Main competitors include Medtronic (MDT) and Tandem Diabetes Care (TNDM). While exact Omnipod 5 market share data is not publicly available, Insulet is a significant player in the AID market.
- Omnipod DASH: The Omnipod DASH Insulin Management System is a tubeless insulin pump that simplifies insulin delivery through a pod and Personal Diabetes Manager (PDM). Competitors include Medtronic (MDT), Tandem Diabetes Care (TNDM), and conventional insulin pens.
Market Dynamics
Industry Overview
The diabetes technology market is experiencing strong growth, driven by increasing prevalence of diabetes, technological advancements in insulin delivery systems, and a growing demand for patient-friendly solutions. Factors such as aging populations and unhealthy lifestyles are contributing to this expansion.
Positioning
Insulet is positioned as a leading innovator in the insulin delivery market, known for its tubeless Omnipod technology. Its competitive advantages lie in its unique product design, ease of use, and focus on patient-centric solutions.
Total Addressable Market (TAM)
The global insulin delivery devices market is projected to reach billions of dollars. Insulet is well-positioned to capture a significant share of this TAM through its innovative products and expanding global presence.
Upturn SWOT Analysis
Strengths
- Innovative Omnipod technology
- Tubeless design enhances user convenience
- Strong brand recognition
- Growing user base
- Expanding global presence
Weaknesses
- Reliance on a single product line
- Potential supply chain vulnerabilities
- Relatively higher cost compared to traditional insulin pumps and pens
Opportunities
- Expanding into new geographic markets
- Developing next-generation insulin delivery systems
- Integrating with other diabetes management technologies
- Leveraging data analytics to improve patient outcomes
- Partnerships with digital health platforms
Threats
- Intense competition from established players
- Price pressures from payers and insurers
- Technological disruptions by new entrants
- Regulatory changes
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- MDT
- TNDM
Competitive Landscape
Insulet's competitive advantage lies in its tubeless Omnipod technology. However, it faces stiff competition from Medtronic and Tandem Diabetes Care, which offer advanced closed-loop systems.
Growth Trajectory and Initiatives
Historical Growth: Insulet has experienced strong revenue growth in recent years, driven by increasing adoption of the Omnipod system.
Future Projections: Future growth projections are based on analyst estimates and company guidance, driven by continued innovation and market expansion.
Recent Initiatives: Recent initiatives include the launch of the Omnipod 5, expansion into new international markets, and strategic partnerships to enhance its technology platform.
Summary
Insulet Corporation is a strong company in the insulin delivery market, driven by its innovative Omnipod technology. Its tubeless design and growing user base contribute to its success. However, the company faces intense competition and needs to continue innovating to maintain its market position. Expanding into new markets and leveraging data analytics could further fuel its growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Insulet Investor Relations
- Market Research Reports
- Analyst Estimates
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. Consult with a financial professional before making any investment decisions. Market share data is approximate and based on available sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Insulet Corporation
Exchange NASDAQ | Headquaters Acton, MA, United States | ||
IPO Launch date 2007-05-15 | CEO, President & Director Ms. Ashley A. McEvoy | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3900 | Website https://www.insulet.com |
Full time employees 3900 | Website https://www.insulet.com | ||
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.